1. Medicines
  2. Dermatology
  3. COSENTYX® (secukinumab)
  4. UnoReady® 300mg pen

Prescribing information

 

UnoReady® 300mg pen

Cosentyx is indicated for the treatment of: moderate to severe plaque psoriasis in adults who are candidates for systemic therapy; active psoriatic arthritis in adult patients, alone or in combination with MTX, when the response to previous DMARD therapy has been inadequate.

Administered by subcutaneous injection at weeks 0, 1, 2, 3 and 4, followed by monthly maintenance dosing. Each 300mg dose is given as two injections of 150mg or one injection of 300mg. Plaque Psoriasis: Adult recommended dose 300mg. Psoriatic Arthritis: Recommended doses are 300mg in patients with concomitant moderate to severe plaque psoriasis or who are anti-TNFα inadequate responders, 150mg in other patients. Can be increased to 300mg based on clinical response.

All the benefits of the Complete Cosentyx Approach™* in plaque psoriasis, now in ONE UnoReady® pen1–3

Image. UNOREADY® 300mg PEN key features.

 

UnoReady® 300mg pen:
Similar administration steps as the SensoReady® 150mg pen, with a few differences.1,4,5

 

 

 

The UnoReady® 300mg pen will be available via homecare channels and your pharmacy.
If you would like to order a demo-kit or for further information on the UnoReady® 300mg pen, please contact us here

 

ONE monthly maintenance injection that delivers 
all the benefits of the Complete Cosentyx Approach1* 

Image for Look Better

Image for Move Better

Image of Feel Better

 

*The Complete Cosentyx Approach™ is defined as efficacy in both skin and persistent nail and scalp PsO, as well as psoriatic arthritis, and improvements in quality of life.
†N=37, moderate-to-severe plaque psoriasis patients at Week 28.2
‡In a clinical study, adverse events with the preferred term injection-site bruising or injection-site pain due to administration of Cosentyx using the UnoReady® pen over 52 weeks.

 

DMARD, disease-modifying anti-rheumatic drugs; MTX, methotrexate; NSAIDs, non-steroidal anti-inflammatory drugs; PsA, psoriatic arthritis; PsO, moderate-to severe plaque psoriasis.

 

References

  1. Cosentyx Summary of Product Characteristics.
  2. Novartis data on file. CAIN457A2325 Data Analysis Report. Satisfaction with self-injection. December 2020.
  3. Novartis data on file. CAIN457A2325 Data Analysis Report. Injection site reaction rate. December 2020.
  4. Cosentyx EPAR Product Information. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/cosentyx Accessed February 2021.
  5. Paul C et al. J Eur Acad Dermatol Venereol. 2015;29(6):1082-1090.
UK | April 2021 | 108723
Dermatology
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]